EP2827862 - Bibliographic data
FORMULATIONS DE BENDAMUSTINE
| Last update | 09/07/2025 |
|---|---|
| Legal status | Brevet déchu |
| Origin | Euro-PCT |
| (73) Holder |
Eagle Pharmaceuticals, Inc. 50 Tice Boulevard
Suite 315
Woodcliff Lake, NJ 07677
États-Unis d'Amérique
|
|---|---|
| (72) Inventors |
Srikanth SUNDARAM 138 Emerson Road
Somerset, New Jersey 08873
États-Unis d'Amérique
|
| (74) Agent |
Mail recipient Carpmaels & Ransford LLP One Southampton Row
London WC1B 5HA
Royaume-Uni
|
| (21) Request number | EP13764989.3 |
|---|---|
| (22) Request date | 15/03/2013 |
| (11) Publication number | EP2827862 |
|---|---|
| Publication date | 27/12/2023 |
| (54) Title of the invention | FORMULATIONS DE BENDAMUSTINE |
|---|---|
| (51) International classification | A61K 31/4184, A61K 47/10, A61K 47/20, A61K 9/00 |
| International classification (before reform) | None |
| Claimed priority |
(31) Number: 201261613173 P |
|---|---|
| Initial application | None |
| Divisional application | EP23218288.1 /EP4360621 None |
| Expected annuity |
Annuity: 12 -
Amount: 285 € -
Due date 02/04/2024
Surtax: 12 - Amount: 57 € - Due date 03/10/2024 |
|---|---|
| Last annuity | None |
| Publication | None |
|---|---|
| History | Publication de la délivrance du brevet européen - Legal date 27/12/2023 Entrée en période de grâce du brevet d'invention - Legal date 03/04/2024 Déchéance du brevet d'invention après période de grâce - Legal date 02/04/2024 |